Adherence to HAART: Perspectives from clients in treatment support programs

Psychology, Health and Medicine

Volumn 11, Issue 2, 2006, Pages 155-170

  Weiss, Linda ^a   French, Tyler ^b   Waters, Mark ^b   Netherland, Julie ^a   Agins, Bruce ^b   Finkelstein, Ruth ^a  

^a NEW YORK ACADEMY OF MEDICINE   (United States)

^b NEW YORK STATE DEPARTMENT OF HEALTH   (United States)

Author keywords

Adherence; Adherence support; AIDS; HAART; HIV

Indexed keywords

ANTIRETROVIRUS AGENT; COCAINE; DIAMORPHINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AFRICAN AMERICAN; ARTICLE; CAUCASIAN; CLINICAL ARTICLE; CONTROLLED STUDY; DOCTOR PATIENT RELATION; DRUG EFFICACY; FEMALE; HEALTH CARE UTILIZATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERPERSONAL COMMUNICATION; INTERVIEW; MALE; MENTAL DISEASE; MOTIVATION; OPEN ENDED QUESTIONNAIRE; PATIENT COMPLIANCE; PATIENT EDUCATION; PHARMACIST; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; SKILL; SOCIAL SUPPORT; SUPPORT GROUP;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COUNSELING; DEMOGRAPHY; FEMALE; HIV INFECTIONS; HUMANS; INTERPROFESSIONAL RELATIONS; INTERVIEWS; INTERVIEWS AS TOPIC; MALE; MIDDLE AGED; PATIENT COMPLIANCE; SOCIAL SUPPORT;

EID: 33745713350     PISSN: 13548506     EISSN: None     Source Type: Journal    
DOI: 10.1080/13548500500159430     Document Type: Article

References (45)

1. Ammassari, A., Murri, R., Pezzotti, P., Paola Trotta, M., Ravasio, L., De Longis, P., et al. (2001). Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV Infection. JAIDS, 28, 445-449.
2. Ammassari, A., Paola Trotta, M., Murri, R., Castelli, F., Narciso, P., Noto, P., et al. (2002). Correlates and predictors of adherence to highly active antiretroviral therapy: Overview of published literature. JAIDS, 31, S123-S127.
3. Arnsten, J., Demas, P., Grant, R., Gourevitch, M., Farzadegan, H., Howard, A., et al. (2002). Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. Journal of General Internal Medicine, 17, 377-381.
4. Bamberger, J. D., Unick, J., Klein, P., Fraser, M., Chesney, M., & Katz, M. (2000). Helping the urban poor stay with antiretroviral HIV drug therapy. American Journal of Public Health, 90(5), 699-701.
5. Broadhead, R. S., Heckathorn, D. D., Altice, F. L., van Hulst, Y., Carbone, M., Friedland, G. H., et al. (2002). Increasing drug users' adherence to HIV treatment: Results of a peer-driven intervention feasibility study. Social Science and Medicine, 55, 235-246.
6. Carr, A., & Cooper, D. A. (2000). Adverse effects of antiretroviral therapy. The Lancet, 356, 1423-1430.
7. Catz, S., Kelly, J. A., Bogart, L. M., Benotsch, E. G., & McAuliffe, T. L. (2000). Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychology, 19(2), 124-133.
8. Chiasson, M., Berenson, L., Li, W., Schwartz, S., Singh, T., Forlenza, S., et al. (1999). Declining HIV/AIDS mortality in New York City. JAIDS, 21(1), 59-64.
9. Duran, S., Spire, B., Raffi, F., Walter, V., Bouhour, D., Journot, V., et al. (2001). Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clinical Trials, 21(1), 38-45.
10. Fairley, C., Levy, R., Rayner, C., Allardice, K., Costello, K., Thomas, C., et al., & Melbourne Adherence Group. (2003). Randomized trial of an adherence programme for clients with HIV. International Journal of STD & AIDS, 14, 805-809.
11. Fogarty, L., Roter, D., Larson, S., Burke, J., Gillespie, J., & Levy, R. (2002). Patient adherence to HIV medication regimens: A review of published and abstract reports. Patient Education and Counseling, 46, 93-108.
12. Friis-Moller, N., Weber, R., Reiss, P., Thiebaut, R., Kirk, O., d'Arminio Monforte, A., et al. (2003). Cardiovascular disease risk factors in HIV patients - Association with antiretroviral therapy: Results from the DAD Study. AIDS, 17, 1179-1193.
13. Galli, M., Ridolfo, A. L., Adorni, F., Gervasoni, C., Ravasio, L., Corsico, L., et al. (2002). Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors. JAIDS, 29, 21-31.
14. Gordillo, V., del Amo, J., Soriano, V., & Gonzalez-Lahoz, J. (1999). Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS, 13, 1763-1769.
15. Haynes, R. B., McDonald, H. P., & Garg, A. X. (2002). Helping patients follow prescribed treatment: Clinical applications. JAMA, 288(22), 2880-2883.
16. Holzemer, W. L., Corless, I., Nokes, K., Turner, J. G., Brown, M. A., Powell-Cope, G. M., et al. (1999). Predictors of self-reported adherence in persons living with HIV disease. AIDS Patient Care and STDS, 13, 3.
17. Howard, A., Arnsten, J., Lo, Y., Vlahov, D., Rich, J., Schuman, P., et al. (2002). A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS, 16, 2175-2182.
18. Justman, J. E., Benning, L., Danoff, A., Minkoff, H., Levine, A., Greenblatt, R. M., et al. (2003). Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. JAIDS, 32, 298-302.
19. Laws, M. B., Wilson, I. B., Bowser, D. M., & Kerr, S. E. (2000). Taking antiretroviral therapy for HIV infection: Learning from patients' stories. Journal of General Internal Medicine, 15, 848-858.
20. Lee, L., Karon, J., Selik, R., Neal, J., & Fleming, P. (2001). Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984-1997. JAMA, 285(10), 1308-1315.
21. Mannheimer, S. (2003). Successful Interventions for Antiretroviral Adherence. Paper presented at the 41st Annual Meeting of the Infectious Diseases Society of America, San Diego, CA.
22. Mannheimer, S., Hirsch, Y., & El-Sadr, W. (1998). The Impact of the ALR Alarm Device on Antiretroviral (AR) Adherence Among HIV-Infected Outpatients in Harlem. Paper presented at the 12th International Conference on AIDS, Geneva.
23. Max, B., & Sherer, R. (2000). Management of the adverse effects of antiretroviral therapy and medication adherence. Clinical Infectious Diseases, 30(Supplement 2), S96-S116.
24. McPherson-Baker, S., Malow, R., Penedo, F., Jones, D., Schneiderman, N., & Klimas, N. (2000). Enhancing adherence to combination antiretroviral therapy in non-adherent HIV-positive men. AIDS Care, 12(4), 399-404.
25. Mocroft, A., Devereux, H., & Kinloch-de-Loes, S. (2000). Immunological, virological, and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. AIDS, 14(11), 1545-1552.
26. Mouton, Y., Alfandari, S., Valette, M., Cartier, F., Dellamonica, P., Humbert, G., et al. (1997). Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. AIDS, 11(12), F101-F105.
27. Nunez, M., Lana, R., Mendoza, J. L., Martin-Carbonero, L., & Soriano, V. (2001). Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. JAIDS, 27, 426-431.
28. Ostrop, N., & Gill, M. J. (2000). Antiretroviral medication and persistence with respect to adherence tool usage. AIDS Patient Care and STDS, 14(7), 351-358.
29. Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., et al. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New England Journal of Medicine, 338(13), 853-860.
30. Palmer, N. B., Salcedo, J., Miller, A. L., Winiarski, M., & Arno, P. (2003). Psychiatric and social barriers to HIV medication adherence in a triply diagnosed methadone population. AIDS Patient Care and STDS, 17(12), 635-644.
31. Paola Trotta, M., Ammassari, A., Melzi, S., Zaccarelli, M., Ladisa, N., Sighinolfi, L., et al. (2002). Treatment-related factors and highly active antiretroviral therapy adherence. JAIDS, 31, S128-S131.
32. Proctor, V. E., Tesfa, A., & Tompkins, D. C. (1999). Barriers to adherence to highly active antiretroviral therapy as expressed by people living with HIV/AIDS. AIDS Patient Care and STDS, 13(9), 535-544.
33. Rakotoambinina, B., Medioni, J., Rabian, C., Jubault, V., Jais, J.-P., & Viard, J.-P. (2001). Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor. JAIDS, 27, 443-449.
34. Remien, R. H., Hirky, A. E., Johnson, M. O., Weinhardt, L. S., Whittier, D., & Le, G. M. (2003). Adherence to medication treatment: A qualitative study of facilitators and barriers among a diverse sample of HIV + men and women in four U.S. cities. AIDS and Behavior, 7(1), 61-72.
35. Rigsby, M., Rosen, M. I., Beauvais, J. E., Cramer, J. A., Rainey, P. M., O'Malley, S. S., et al. (2000). Cue-dose training with monetary reinforcement: A pilot study of an antiretroviral adherence intervention. Journal of Developmental and Behavioral Pediatrics, 15, 841-847.
36. Roberts, K. J. (2000). Barriers to and facilitators of HIV-positive patients' adherence to antiretroviral treatment regimens. AIDS Patient Care and STDS, 14(3), 155-168.
37. Sankar, A., Luborsky, M., Schuman, P., & Roberts, G. (2002). Adherence discourse among African-American women taking HAART. AIDS Care, 14(2), 203-218.
38. Sorensen, J. L., Mascovich, A., Wall, T. L., DePhilippis, D., Batki, S. L., & Chesney, M. A. (1998). Medication adherence strategies for drug abusers with HIV/AIDS. AIDS Care, 10(3), 297-312.
39. Starace, F., Ammassari, A., Paola Trotta, M., Murri, R., De Longis, P., Izzo, C., et al. (2002). Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy. JAIDS, 31, S136-S139.
40. Tuldra, A., Fumaz, C., Ferrer, M. J., Bayes, R., Arno, A., Balague, M., et al. (2000). Prospective randomized two-arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy. JAIDS, 25, 221-228.
41. Turner, B. (2002). Adherence to antiretroviral therapy by human immunodeficiency virus-infected patients. Journal of Infectious Diseases, 185(Supplement 2), S143-151.
42. Wall, T. L., Sorensen, J. L., Batki, S. L., Delucchi, K. L., London, J. A., & Chesney, M. A. (1995). Adherence to zidovudine (AZT) among HIV-infected methadone patients: A pilot study of supervised therapy and dispensing compared to usual care. Drug and Alcohol Dependence, 37, 261-269.
43. Waters, M., Hoos, D., Agins, B., Savicki, C., Devore, B., Glaros, R., et al. (1998). Service Delivery Models for Treatment Adherence to Combination Antiretroviral Therapy. Paper presented at the XII International Conference on AIDS, Geneva.
44. Whitman, S., Murphy, J., Cohen, M., & Sherer, R. (2000). Marked declines in human immunodeficiency virus-related mortality in Chicago in women, African Americans, Hispanics, young adults, and injection drug users, from 1995 through 1997. Archives of Internal Medicine, 160(3), 365-369.
45. Wong, T., Chiasson, M., & Reggy, A. (2000). Antiretroviral therapy and declining AIDS mortality in New York City. Journal of Urban Health, 77(3), 492-500.